Drugs / LESINIDASE ALFA
LESINIDASE ALFA
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02618512 | Oct 2015 → Aug 2017 | mucopolysaccharidosis type 3B | Alexion Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT02324049 | Jan 2015 → Oct 2017 | mucopolysaccharidosis type 3B | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LESINIDASE ALFA | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990017 ↗ |
| Known as | Lesinidasa alfa | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990017 ↗ |
| Known as | rhNAGLU | “SBC-103 is a recombinant human alpha-N-acetylglucosaminidase (rhNAGLU).” NCT02618512 ↗ |
| Known as | SBC-103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02324049 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human alpha-N-acetylglucosaminidase” NCT02324049 ↗ |
| Route | Intravenous | “SBC-103 Administered Intravenously” NCT02324049 ↗ |